NCT00807170View on ClinicalTrials.gov

Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

ZD6474 (Vandetanib)

100 mg as a once daily oral dose, 21 days

RADIATION

Whole Brain Radiotherapy (WBRT)

DRUG

ZD6474

200 mg as a once daily oral dose, 21 days

DRUG

ZD6474

300 mg as a once daily oral dose, 21 days

Trial Locations (3)

Unknown

Research site, Amsterdam

Research site, Groningen

Research site, Maastricht

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00807170 - Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases | Biotech Hunter | Biotech Hunter